Seeking Alpha

Gilead Sciences (GILD +5.9%) trades higher after investors further digest the ramifications of...

Gilead Sciences (GILD +5.9%) trades higher after investors further digest the ramifications of its mega-acquisition of Pharmasset (VRUS -0.1%) that sent shares skittishly lower yesterday. Citi took a look at the deal, deciding to upgrade GILD to Buy from Neutral, seeing a potential for the now-bigger company to dominate the Hepatitis C treatment market.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs